Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Mesothelioma, Malignant × nintedanib × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 2 Radiation Pneumonitis 1 Patients With Any Advanced Solid Tumors 1 Mesothelioma, Malignant 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Endometrial Neoplasms 1 Breast Neoplasms 1

Interventions

Cisplatin 15 Pemetrexed 12 pembrolizumab 8 Nivolumab 8 Carboplatin 7 Ipilimumab 5 Cyclophosphamide 5 Platinum 4 1,2-diaminocyclohexaneplatinum II citrate 4 Gemcitabine 3 Drug Therapy 3 tremelimumab 2 fludarabine 2 durvalumab 2 atezolizumab 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Radiation 2 Photochemotherapy 2 Methotrexate 2 Interleukin-2 2 Chemotherapy, Adjuvant 2 sargramostim 1 olaparib 1 niraparib 1 nintedanib 1 methoxyamine 1 lenvatinib 1 enzalutamide 1 decitabine and cedazuridine drug combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02863055 2025-09-19

NEMO

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Terminated

Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡